Source - SMW
GlaxoSmithKline has announced the regulatory submission of a Marketing Authorisation Application to the European Medicines Agency seeking approval of subcutaneous formulation of sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). 

The MAA seeks approval for sirukumab in combination with methotrexate in RA patients who have failed or are intolerant to conventional or biologic disease-modifying antirheumatic drugs (DMARDs) and as a monotherapy in these patients for whom treatment with methotrexate is inappropriate.   Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen].  

At 3:21pm: (LON:GSK) GlaxoSmithKline PLC share price was -9.75p at 1589.75p